Since the recognition of the risks of exposure to lead, standards of environmental and industrial hygiene have improved and acute lead intoxication is not commonly seen. It has become apparent, however, that chronic exposure to lead may lead to irreversible sequelae with no overt antecedent symptoms of lead toxicity. As renal impairment may occur at any time after exposure to lead, such a history should be sought from any patient with renal failure of uncertain aetiology. If suspected, the diagnosis may be confirmed with the aid of a Calcium Ethylene Diamine Tetra-acetic Acid (Calcium EDTA) chelation test.
Sources of lead
The levels of environmental lead from natural sources are low and most of the atmospheric lead is derived from industrial processes or from the combustion of lead containing petrol. The organo-Iead compounds in petrol, although associated with significant neurological effects, are not associated with renal impairment. Adults at highest risk of lead intoxication are those exposed to lead fumes or dust in industry (1, 2, 12) and as little as 3 months exposure may cause pathological renal lesions (3) . In children, direct ingestion of lead accounts for most of the lead intoxication. Children are more susceptible to the effects of lead intoxication than adults at lower levels of exposure, because of increased gastrointestinal absorption of lead (4, 5) . Lead nephropathy accounted for 4 patients entering end stage renal failure programmes in Austrialia in 1985, although further patients with renal failure of uncertain aetiology may well have had unrecorded significant lead exposure in the past and presented with end stage renal failure (10) .
Acute lead nephropathy
Acute lead nephropathy is now rarely seen. It has been reported mainly in children and manifests as The International Journal Of Artificial Organs / Vol. 11 / no. 2, 1988/ pp. 75-78 proximal tubular dysfunction with phosphaturia, glycosuria, aminoaciduria and renal tubular acidosis. Proteinuria is minimal. These abnormalities may be reversed by treatment with Calcium EDTA chelation therapy (6, 7) .
The histological correlate of acute proximal tubular dysfunction is the presence of eosinophilic intranuclear inclusions which are complexes of lead and protein. Striking destruction of mitochondria is present due to the strong affinity lead has for mitochondrial membrane. The binding of lead in effect reduces the cytoplasmic concentration of lead and decreases the effect of cellular function, e.g. mitochondrial respiration and mitochondrial synthesis (4) . The nuclear inclusions are disrupted and removed by the administration of Calcium EDTA (8).
Chronic lead nephropathy
Although it has been agreed that acute renal dysfunction is a sequelae of acute lead intoxication, the development of chronic renal failure secondary to lead intoxication had not been as widely accepted. Henderson in 1954 followed up 400 children admitted to Brisbane hospitals between 1915 and 1935 with acute lead intoxication. Of these children, 165 had died, 108 had chronic renal failure or hypertension, and a further 20 had hypertension and proteinuria or hypertension alone, representing a vast increase in renal and vascular disease above normal (9) . In a further study (10) , he showed that patients with no obvious cause of chronically contracted kidneys had significantly higher bone lead levels than those with a known cause of renal disease. Despite this evidence linking lead and renal disease, the association of occupational exposure to lead and renal impairment had been disputed, particularly in the United States (11). However, more recent studies have been in agreement with the more widely held view that lead exposure may lead to chronic renal failure, as reduced renal function may be demonstrated in asymptomatic workers with chronic exposure to lead (1, 2, 12) .
Although occupational exposure is the commonest cause of chronic lead nephropathy likely to be seen today, other causes may also occur, e.g. the nephropathy documented in the southern United States due to illicit alcohol abuse (13) or that occuring in patients exposed to water with high lead concentration (14) .
Emmerson's criteria for the diagnosis of chronic lead nephropathy (15) have been widely accepted, ie: 1) Features of long standing renal disease; 2) Moderate to considerable contraction of both kidneys;
3) Definitive evidence of increased past lead absorption; 4) Exclusion of other cause of renal disease. Although diagnostic criteria for excess lead exposure after Calcium EDTA chelation testing differ (12) , this remains the best test for assessing total body lead.
The earliest functional changes in low dose long term exposure are tubular. Hong et al (3) studied six patients with occupational exposure to lead and found the most sensitive test for renal damage to be a decrease in glucose reabsorptive capacity, sometimes evident after as little as 3 months exposure. Generally, the decline in renal function parallels the duration and concentration of exposure (13) . Significant decreases in glomerular filtration rate may occur in the face of 'acceptable' blood lead levels (18) , before screening tests such as blood urea or serum creatinine become abnormal (16, 17) .
Histology
Light microscopic changes in chronic lead nephropathy are nonspecific. They include glomerular obsolescence, periglomerular fibrosis, diffuse abnormalities of the proximal tubular cells, focal tubular atrophy, interstitial fibrosis, and a paucity of inflammatory infiltrate. Vascular lesions in small arteries and arterioles vary, with medial thickening, intimal proliferation, and at times hyalinization of arterial walls (16) . The lead inclusion bodies which characterise the acute histological lesion are rarely seen (14) . In a study of Cramer et al (19) , nuclear inclusions were seen only in two patients exposed to lead for less than 12 months. The cause for this is unknown but may be due to increased renal cell turnover or as a consequence of prior treatment in some cases. Other nuclear changes, such as clumped granular chromatin and nuclear invagination of cytoplasmic contents, may be seen in other forms of chronic renal failure. Mitochondria in tubular cells are distorted, and the endoplasmic reticulum is swollen and occasionally increased. Lysosomal elements are increased. Brush borders of the 76 proximal tubule are lost and proximal tubule basement membrane thickening is present. Glomeruli show non specific abnormalities such as occasional swelling and distortion of organelles in the cytoplasm but normal basement membrane thickness without fusion of foot processes (14, 19) .
The immunofluorescence findings are not well documented. IgG, IgM and C3 are found in varying amounts in glomerular capillaries and tubular basement membrane (14) . Nevertheless, an 'immune mechanism' for the initiation or progression of renal pathology cannot be excluded.
Cramer et al (19) thus postulate 3 stages in the development of renal failure after exposure to lead: 1) Early phase -less than one year exposu re, wh ich is reversible.
2) Intermediate phase -after 4 years exposure, which may be reversible.
3) Renal failure. Despite the described retrospective studies, the progression to renal failure has not yet been confirmed in prospective studies from early lesions, although animal studies support this view.
Gout and lead nephropathy
Gout and hyperuricemia rarely cause renal disease, as shown by Batuman et al (20) . Conversely, clinical evidence of gout is rare in other forms of renal disease. However, in lead nephropathy gout is present so often (20, 21) that the coincidence of gout and renal failure should suggest lead as the underlying cause.
The hyperuricemia is due to increased tubular resorption of urate (12) but it may also be contributed to by lead induced inhibition of guanine aminohydrolase (23) .
Lead nephropathy and hypertension
The association between lead nephropathy and hypertension has been studied by Batuman et al (24) who demonstrated greater lead loads in patients with both hypertension and renal impairment compared with either hypertension or renal impairment alone. This finding has been confirmed by others (25) , although not universally so (14, 26) . Histological diagnosis of hypertensive nephrosclerosis and lead neph-ropathy is difficult, because the vascular changes seen in hypertension are also seen in lead nephropathyeven in the absence of hypertension.
Diagnosis of lead nephropathy
At the time of presentation with renal impairment, a history of exposure to lead may be difficult to elicit. If the diagnosis is considered it should be confirmed with the aid of a Calcium EDTA chelation test. Other diagnostic methods such as blood lead levels, erythrocyte and zinc protoporphyrins, serum and urine delta-amino-Ievulinic acid and urinary coproporphyrins, while useful if exposure is recent give little information regarding past exposure (27) . Radiological demonstration of 'lead lines' at metaphyseal ends of bone are rarely seen. X-ray fluorescence is not a sensitive test for lead intoxication (28) . Hair lead concentration greater than 80 Jig/g may indicate toxicity but may be influenced by other factors such as hair colour and age. As lead in bone has a half life of 19 years (29) , elevations in bone lead are expected in patients with lead nephropathy. Urinary lead levels without prior chelation are insensitive and influenced by urine flow rate and specific gravity.
Measurement of urinary lead levels following administration of Calcium EDTA is the most reliable indicator of past lead exposure (12) . Calcium EDTA acts as an ion exchange resin for lead, resulting in a water soluble complex which is excreted in the urine. In adults, one gramme of Calcium EDTA is administered intravenously over a period varying between 20 minutes and 24 hours. Alternatively, two grammes may be administered intramuscularly in divided doses twelve hours apart. In subjects with normal renal function, most of the lead is excreted in the first 24 hours; if renal impairment is present, clearance of the lead is reduced and urine should be collected for assay for 72 hours from initiation of chelation. Reported normal daily lead excretion following chelation varies between 350 to 600 JiB (1.69 to 2.9 Jimol) (12) . Higher levels indicate a significance excess body lead burden and treatment utilizing daily Calcium EDTA in similar dosages as the test dose for 5 to 10 days should be undertaken.
In children, from 50 mg/kg to a maximum of one gramme of Calcium EDTA is administered intraven-ously and a ratio of lead excreted (J1g) over 24 hours to Calcium EDTA given (mg) of grater than 0.6 to 1.0 indicates toxicity.
Other methods of treatment of lead intoxication such as dimercaprol, penicillamine, dimercaptosuccinic acid and 2, 3-dimercaptopropane, although useful for non-renal manifestations of lead intoxication, have not been of proven use in lead nephropathy.
In acute lead nephropathy treatment with Calcium EDTA has restored renal function rapidly to normal (6) . In chronic lead nephropathy, Calcium EDTA treatment has been shown to be of some use in improving renal function (14) . Glomerular filtration rate may increase by up to 20% with long term chelation therapy (17, 18) , but if marked light microscopic changes are present, these are irreversible and minimal improvement in renal function will be expected from treatment. A course of chelation therapy should be undertaken once the diagnosis of lead nephropathy is established, but if renal function fails to improve further chelation should not be undertaken with the sole aim being to improve renal function. Of course, meticulous attention to other factors such as blood pressure control and dietary factors should also be addressed to retard the progression of renal disease.
In summary, chronic lead nephropathy is a not uncommon cause of renal failure but the diagnosis will often be missed in patients presenting with small scarred kidneys and no obvious cause of renal disease when an accurate personal and occupational history is not undertaken. It should be particularly considered when gout and hypertension are associated features. If suspected, the diagnosis should be confirmed by a Calcium EDTA chelation test.
